DDInter150 DDInter1840
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Azathioprine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Azathioprine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Azathioprine {u} (Compound) downregulates {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Azathioprine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) and {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Azathioprine {u} (Compound) treats {v} (Disease) ulcerative colitis
ulcerative colitis {u} (Disease) is associated with {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Azathioprine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Azathioprine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Azathioprine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Azathioprine (Compound) downregulates SLC5A6 (Gene) and SLC5A6 (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Azathioprine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with SRC (Gene) and STUB1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Azathioprine (Compound) treats ulcerative colitis (Disease) and ulcerative colitis (Disease) is associated with PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Azathioprine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)